Sarcoma / 2019 / Article / Fig 1

Clinical Study

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

Figure 1

Waterfall plots for best response by the WHO (a) and RECIST (b) and changes in plasma VEGF (c) and VEGFR2 (d) in patients with paired samples at baseline and prior to cycles 3 (N = 13) and 5 (N = 8).
(a)
(b)
(c)
(d)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.